Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
252
-
Total 13F shares, excl. options
-
50.9M
-
Shares change
-
+1.04M
-
Total reported value, excl. options
-
$6.12B
-
Value change
-
+$155M
-
Put/Call ratio
-
1.99
-
Number of buys
-
118
-
Number of sells
-
-145
-
Price
-
$120.34
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2019
307 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q2 2019.
HAEMONETICS CORP - Common Stock (HAE) has 252 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.9M shares
.
Largest 10 shareholders include BlackRock Inc. (6M shares), WELLINGTON MANAGEMENT GROUP LLP (5.98M shares), VANGUARD GROUP INC (5.6M shares), Capital Research Global Investors (2.55M shares), RENAISSANCE TECHNOLOGIES LLC (2.48M shares), Neuberger Berman Group LLC (2.18M shares), Jackson Square Partners, LLC (1.96M shares), STATE STREET CORP (1.72M shares), WELLS FARGO & COMPANY/MN (1.13M shares), and FRANKLIN RESOURCES INC (1.02M shares).
This table shows the top 252 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.